+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Statin use and the risk of breast and prostate cancer



Statin use and the risk of breast and prostate cancer



Epidemiology 13(3): 262-267



Laboratory data suggest that the cholesterol-lowering "statin" drugs may have chemopreventive potential against cancer at various sites, including breast and prostate. However, in one trial of pravastatin there was a significant excess of breast cancer in the treatment group. In the present study, we assessed the relation of statin use to the risk of breast and prostate cancer in our hospital-based Case-Control Surveillance Study of Drugs and Serious Illnesses. Cases were 1,132 women with breast cancer and 1,009 men with prostate cancer; controls were 1,331 women and 1,387 men admitted for conditions unrelated to statin use. We used multivariate unconditional logistic regression models to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for use of statins compared with no use. The OR for breast cancer among statin users was 1.5 (95% CI = 1.0-2.3), largely accounted for by an OR of 1.8 (95% CI = 0.9-3.6) among cases with carcinoma in situ. Among invasive cases, the OR was 1.2 (95% CI = 0.7-2.0). The odds ratio for prostate cancer overall was 1.2 (95% CI = 0.8-1.7), and it was 1.4 (95% CI = 0.7-2.5) for Stage A. The data from the present study do not support a protective effect of statins against breast or prostate cancer. Detection bias is a possible explanation for the higher ORs observed for carcinoma in situ or early-stage cancer as compared with more invasive cancer.

(PDF emailed within 0-6 h: $19.90)

Accession: 047433498

Download citation: RISBibTeXText

PMID: 11964926

DOI: 10.2307/3703395


Related references

CYP17 genetic variation and risk of breast and prostate cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). Cancer Epidemiology, Biomarkers & Prevention 16(11): 2237-2246, 2007

Prostate cancer (PCa) risk variants and risk of fatal PCa in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. European Urology 65(6): 1069-1075, 2015

Genome-wide scan of high-risk prostate cancer families with breast cancer reveals novel prostate-breast loci. American Journal of Human Genetics 67(4 Supplement 2): 93, October, 2000

PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3). Carcinogenesis 31(3): 455-461, 2010

Statin and NSAID use and prostate cancer risk. Pharmacoepidemiology and Drug Safety 19(7): 752-755, 2010

Statin Use and Risk of Prostate Cancer in MrOS. 2012

Statin drugs and risk of advanced prostate cancer. Journal of the National Cancer Institute 98(24): 1819-1825, 2006

Statin use and the risk of prostate-specific antigen recurrence after radiation therapy with or without hormone therapy for prostate cancer. Journal of Clinical Oncology 28(16): 2651-2652, 2010

The risk of prostate cancer for men on aspirin, statin or antidiabetic medications. European Journal of Cancer 51(6): 725-733, 2015

Statin drug use is not associated with prostate cancer risk in men who are regularly screened. Journal of Urology 192(2): 379-384, 2014

Re: Statin drugs and risk of advanced prostate cancer (PC) - Platz. 2007

Statin use and risk of prostate cancer in a population of men who underwent biopsy. Journal of Urology 186(1): 86-90, 2011

Statin use and the risk of breast cancer. Journal of Clinical Epidemiology 56(3): 280-285, 2003

Statin use and risk of breast cancer. Cancer 112(1): 27-33, 2007

Sequence variants of estrogen receptor beta and risk of prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiology, Biomarkers & Prevention 16(10): 1973-1981, 2007